GSK and Chinese biotech unite for coronavirus vaccine development

British drugmaker GSK and Chinese biotech Clover Biopharmaceuticals have partnered to develop a protein-based coronavirus vaccine candidate.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

14 April 2020 Sanofi and GlaxoSmithKline are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Americas

Vir Biotech partners with WuXi on COVID-19 antibody treatment

27 February 2020 Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.

Americas

Sanofi partners with HHS to work on COVID-19 vaccine

19 February 2020 Sanofi’s vaccine unit has united with the US Department of Health and Human Services to develop a vaccine for the COVID-19 virus, which has so far killed more than 2,000 people worldwide.

More on this story

Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

14 April 2020 Sanofi and GlaxoSmithKline are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Americas

Vir Biotech partners with WuXi on COVID-19 antibody treatment

27 February 2020 Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.

Americas

Sanofi partners with HHS to work on COVID-19 vaccine

More on this story

Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

14 April 2020 Sanofi and GlaxoSmithKline are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Americas

Vir Biotech partners with WuXi on COVID-19 antibody treatment

27 February 2020 Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.

Americas

Sanofi partners with HHS to work on COVID-19 vaccine